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in pediatrics. Therefore, formulation of taste-masked 
products is a challenge to the pharmacists.[3,4]
Ondansetron HCl is a potent antiemetic drug indicated 
for the treatment and/or prophylaxis of postoperative or 
chemotherapy- or radiotherapy-induced emesis, and is also 
used in the early onset of alcoholism.[5] In general, emesis is 
preceded with nausea and, in such a condition, it is difficult 
to the administer drug with a glass of water. Hence, it is 
beneficial to administer such drugs as orodispersible tablets 
(ODTs). Ondansetron HCl is an intensely bitter drug; 
hence, if it is incorporated directly into an ODT, the main 
objective behind formulation of such a dosage form will 
definitely be futile.[6] Thus, in the present study, an attempt 
has been made to mask the taste of ondansetron HCl and 
INTRODUCTION
Convenience of administration and patient compliance 
are gaining significant importance in the design of 
dosage forms. Recently, more stress is laid down on the 
development of an organoleptically elegant and patient-
friendly drug delivery system for pediatric and geriatric 
patients.[1,2] More than 50% of the pharmaceutical 
products are orally administered for several reasons, and 
undesirable taste is one of the important formulation 
problems encountered with such oral products. Taste 
of a pharmaceutical product is an important parameter 
for governing compliance. Thus, taste masking of oral 
pharmaceuticals has become an important tool to improve 
patient compliance and the quality of treatment, especially 
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ABSTRACT
Ondansetron hydrochloride is an intensely bitter antiemetic drug used to treat nausea and vomiting following 
chemotherapy. The purpose of the present work was to mask the taste of ondansetron hydrochloride and to 
formulate its patient-friendly dosage form. Complexation technique using indion 234 (polycyclic potassium with 
carboxylic functionality) and an ion-exchange resin was used to mask the bitter taste and then the taste-masked 
drug was formulated into an orodispersible tablet (ODT). The drug loading onto the ion-exchange resin was 
optimized for mixing time, activation, effect of pH, mode of mixing, ratio of drug to resin and temperature. The 
resinate was evaluated for taste masking and characterized by X-ray diffraction study and infrared spectroscopy. 
ODTs were formulated using the drug–resin complex. The developed tablets were evaluated for hardness, friability, 
drug content, weight variation, content uniformity, friability, water absorption ratio, in vitro and in vivo disintegration 
time and in vitro drug release. The tablets disintegrated in vitro and in vivo within 24 and 27 s, respectively. Drug 
release from the tablet was completed within 2 min. The obtained results revealed that ondansetron HCl has 
been successfully taste masked and formulated into an ODT as a suitable alternative to the conventional tablets.
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to formulate ODTs with a good mouth feel so as to prepare 
a “patient-friendly dosage form.”
Mouth-dissolving tablets are dosage forms that disintegrate 
in patient’s mouth within a few seconds without the need 
of water, or chewing, providing best remedy for patients 
suffering from dysphagia. Their growing importance was 
underlined recently when the European pharmacopoeia 
adopted the term “orodispersible tablet” as a tablet that is 
to be placed in the mouth where it disperses rapidly before 
swallowing.[7]
Ion-exchange resins have been increasingly used as taste-
masking agents. They are also known to be useful as 
disintegrating agents.[8,9] Thus, the study undertaken was 
aimed at using ion-exchange resins for both the purposes, 
formulating taste-masked ODTs of ondansetron HCl.
The complex of cationic drug and weak ion-exchange 
resin does not break at the pH of saliva, i.e. 6–7, with a 
cation concentration of 40 meq/l. But, at the high cationic 
concentration in the stomach and pH 1.2, free drug is 
immediately released. This implies that while passing 
through the mouth, the drug remains in the complex 
form, thereby imparting no bitter taste in the mouth. This 
property was exploited to formulate the “consumer-friendly 
dosage form,” i.e. mouth-dissolving tablets.[10]
MATERIALS AND METHODS
Materials
Ondansetron HCl was a gift sample from Alkem 
Laboratories (Mumbai, India). Indion 234 was obtained 
from Ion Exchange India Ltd., Mumbai, India. Starlac and 
MCC (PH 101) were provided by Signet Chemicals Ltd., 
Mumbai, India. All other chemicals and reagents used were 
of high analytical grade.
Methods
Preparation of  drug–resin complex (resinate)
Resinate were prepared using the batch method.[11] Water 
is used as a medium for complexation because the drug 
is soluble in water.[12] An accurately weighed amount 
of resin (100 mg) was placed in a beaker containing 50 
ml of deionised water. Accurately weighed 100 mg of 
ondansetron hydrochloride was added to the resin solution 
and stirred for 180 min. The mixture was filtered through a 
Whatman filter paper and the residue was washed with 50 
ml of deionised water to remove any uncomplexed drug. 
Unbound drug in the filtrate was estimated at 310 nm and 
the drug-loading efficiency was calculated.
Optimization of  Ondansetron HCl–indion resin complexation
The drug loading on to the resin was optimized for 
various parameters such as mixing time, activation, effect 
of pH, mode of mixing, ratio of drug:resin and effect of 
temperature.
Optimization for mixing time on drug loading
Separate batches of indion 234 (100 mg) were soaked in 
50 ml of distilled water in a beaker and about 100 mg of 
drug was added and stirred for 3 h. The mixture was filtered 
through a Whatman filter paper and the residue was washed 
with 50 ml of deionized water to remove any uncomplexed 
drug. Unbound drug in the filtrate was estimated at 310 
nm and the time required for maximum adsorption of the 
drug was optimized.
Effect of  activation of  resin on drug loading
Resins were washed with distilled water and subsequently 
with 1 N HCl. The resins were rewashed with water until 
neutral pH was reached. Drug:resin complexes were 
prepared by placing 100 mg of acid-activated resins in 
a beaker containing 50 ml distilled water and about 100 
mg of drug and stirred for 3 h, and the drug content 
was determined as mentioned previously. Similarly, alkali 
activation of indion 234 was performed, replacing 1 N 
HCl with 1 N NaOH.
Effect of  pH, mode of  mixing, ratio of  drug:resin and temperature 
on drug loading
For optimization of pH, weighed, 100 mg of drug was 
added to 100 mg of activated resins in 50 ml of distilled 
water. The pH of the solutions was adjusted at 3.0, 3.5, 
4.0, 4.5, 5.0, 5.5, 6.0 and 6.5 and stirred for 3 h and the 
drug content was determined as mentioned previously.[11]
For optimization of mode of mixing, rotary shaker and 
magnetic stirrer were used. For all activated resins (100 
mg) in 50 ml of distilled water and about 100 mg of drug, 
the pH was adjusted at 3.5 and the drug content was 
determined as mentioned previously. For optimization of 
ratio of drug:resin, three batches were prepared containing 
drug–resin in the ratio of 1:1, 1:2 and 1:3. The pH was 
maintained at 3.5. The solution was stirred using a magnetic 
stirrer for 3 h. To study the effect of temperature, separate 
batches were prepared containing drug–resin in the ratio 
of 1:3. The pH was maintained at 3.5 and was stirred using 
a magnetic stirrer at 30°, 35°, 40°, 50° and 60°C and the 
drug content was determined as mentioned previously.
Characterization of  resinate
FT-IR spectrum of the drug, resin and resinate were 
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recorded over the wave no 4000 to 400 cm-1 on a Jasco 
Dispersive type FT-IR spectrophotometer  using the 
KBr disc technique. Then, the spectra were analyzed to 
determine the formation of complex of the drug and resin.
The drug, resins and resinate was subjected to X-ray 
diffraction study for the confirmation of complex 
formation. X-ray diffraction studies were carried out on a 
Phillips analytical X-ray BV  (pw1710) using Cu anode 40 
kv voltage and 30 mA current.
Determination of  drug content
Resinate equivalent to 8 mg of drug was stirred with 100 
ml of 0.1 N HCL for 3 h, till the entire drug leached out, 
and then the solution was filtered through a Whatman filter 
paper. Further dilutions were made with 0.1 N HCl and 
the drug content was determined spectrophotometrically 
at 310 nm using 0.1 N HCl as blank.
Taste evaluation of  solid drug:resin complex
The drug–resin complex (1:3) was subjected to sensory 
evaluation by a panel of nine members using the time 
intensity method. The pure drug without complexation 
with the ion-exchange resin was used as control in this 
study. Sample equivalent to 8 mg (dose of drug) was held 
in the mouth for 10 s. Bitterness was recorded instantly 
and then after 20, 30, 40, 50 and 60 s. The evaluation 
was performed by classifying bitter taste into five levels: 
level 0: no bitter taste is sensed; 1: acceptable bitterness; 
2: slightly bitter; 3: moderately bitter; 4: strongly bitter. 
Descriptive statistics, mean and standard deviation were 
calculated for all variables. Paired t-test was applied using 
INSTAT software. Value P<0.05 has been considered as 
the statistical significance level.
In vitro dissolution
Complexes of Ondansetron hydrochloride with indion 234 
were subjected to in vitro dissolution studies using the USP 
24 method. Weigh quantity of complexes equivalent to the 
normal dose and suspended in 0.1 N HCl using the USP II 
dissolution apparatus. The quantity of drug released was 
determined periodically.
Formulation development
Resinates of drug (dose of drug 8 mg) were formulated 
into tablet by the direct compression technique. using 
sodium starch glycolate, microcrystalline cellulose (PH-
101) and spray-dried mixture of starch and lactose 
(Starlac). Each formulation was composed of drug and 
excipients in various proportions, as shown in Table 1. 
All ingredients were passed through mesh no. 60. The 
required quantity of each was taken for the particular 
formulation and the blend was mixed using a mixer. 
Powder blend was evaluated for micromeritic properties 
like shape, angle of repose, bulk density, tapped density 
and Housner ratio.[13,14] Mixed blend of drug and 
excipients was compressed on an 8-station rotary punch 
tablet machine (Karnavati, India). Tablets, each weighing 
150 mg, were prepared.
Evaluation of  tablets
The prepared tablets were evaluated for various official 
and nonofficial specifications.[15,16] Twenty tablets were 
selected at random and the average weight was calculated. 
Then, individual tablets were weighed and the individual 
weight was compared with an average weight. Tablets 
were evaluated for hardness and friability testing using 
the Monsanto hardness tester and the Roche friabilator, 
respectively. For drug content uniformity, 20 tablets were 
weighed and crushed. The resinate powder was weighed 
to get 8 mg drug equivalent and transferred to 100 ml of 
0.1 N HCl and shaken for 15 min and centrifuged. Further 
dilutions were made with 0.1 N HCl and the drug content 
was determined spectrophotometrically at 310 nm using 
0.1 N HCl as blank.
Water absorption ratio
A piece of tissue paper folded twice was placed in a small 
Petri dish containing 6 ml of water. A tablet was put on the 
tissue paper and allowed to wet completely.[16] The wetted 
tablet was then weighed. Water absorption ratio, R, was 
determined using the following equation:
         R = 100 x {Wa – Wb}/Wb
Where, Wb = Weight of tablet before water absorption
        Wa = Weight of tablet after water absorption
In vitro dispersion time
The tablet was put into 100 ml distilled water at 37°C   ±   2°C. 
Time required for complete dispersion of a tablet was 
measured with the help of a digital tablet disintegration 
test apparatus.
Table 1: Formulation design
Time (s) Before taste masking 
(mean ± SD)
After taste Masking 
(mean ± SD)
10 4.0 ± 0.00** 0.3 ± 0.44**
20 3.2 ± 0.50** 0.09 ± 0.33**
30 2.4 ± 0.52** 0
40 2.0 ± 0.50** 0
50 1.7 ± 0.44** 0
60 1.22 ± 0.44** 0
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In vivo dispersion time
In vivo dispersion time of a tablet was checked in healthy 
human volunteers by putting a tablet on the tongue and 
measuring the time required for complete dispersion of 
a tablet.
Dissolution study
Tablets formulated with resinates were subjected to in vitro 
dissolution studies using the USP type II apparatus (Paddle 
type) at 100 rpm with a temperature of 37°C   ±   0.5°C. 
Dissolution was carried out in 0.1 N HCl as the 
dissolution medium. After a specific time interval, 5 ml 
of the dissolution medium was withdrawn by a pipette 
and replaced with fresh medium for maintaining the sink 
condition. The sample was filtered and absorbance of 
the filtered solution was determined by UV spectroscopy 
at 310 nm. Dissolution rate was studied for all designed 
formulations and the conventional marketed tablet.
RESULTS AND DISCUSSION
Optimization of  Ondansetron HCl–Indion 234 
complexation
Ondansetron was loaded onto Indion 234 by the batch 
process. Complexation is essentially a process of diffusion 
of ions between the resin and the surrounding drug 
solution. As reaction is an equilibrium phenomenon, 
maximum efficacy is best achieved in batch process.
Complexation between drug and resin increases up to 
the optimum time and then remains almost constant. 
It was found to be optimum after 3 h of mixing in the 
resin investigated. Highest drug binding on the resin was 
achieved when activated with 1 N HCl.
The percentage drug loading with inactivated resin, treated 
with acid and alkali, was found to be 45.55 ± 1.6% w/w, 
54.61 ± 0.5 and 49.65 ± 0.11% w/w, respectively. After 
activation with acid treatment, the exchangeable ion on the 
resin is H+. Relative selectivity of H+ is least than other ionic 
forms and therefore it increases the percent complexation. 
The mode of complexation between drug and resin can be 
affected by pH of the media. Maximum drug loading on 
the resin occurs at pH 3.5; a maximum of 71.79 ± 0.73% 
w/w for indion 234. As pH increases above 3.5, percentage 
of drug loading decreases. pH of the solution affects 
both solubility and degree of ionization of the drug and 
resin. Results can be attributed to the fact that a cationic 
drug is ionized at lower pH value and hence demonstrates 
high binding capacity while at higher pH, the protonated 
fraction of cationic drug decreases and hence interaction 
with resin also decreases.[11] Hence, Ondansetron HCl as a 
cationic drug will have maximum solubility and complete 
ionization in this range. Decreased complexation at lower 
pH, i.e. below 2, is due to excess H+ ions in solution, which 
have a higher binding affinity to the –COO group of the 
resin and compete with the drug for binding. Complexation 
was found to be optimum when using a magnetic stirrer, 
a maximum of 71.79 ± 0.73% w/w for indion 234 and, 
in case of a rotary shaker, a maximum of 65.27 ± 0.54% 
w/w. This finding may indicate the significant involvement 
of van der Vaal’s forces taking place along with drug 
exchange during complexation. The drug loading in various 
drug:resin concentrations was found to be 71.79 ± 0.73% 
w/w, 78.24 ± 0.86% w/w, 83.82 ±0.57% w/w for 1:1, 1:2 
and 1:3 ratio, respectively. Increase in drug resin ratio above 
1:3 did not further increase the percentage drug loading. 
The % drug loading (w/w) with temperature of 30°, 35°, 
40°, 50° and 60°C was found to be 76.82 ± 0.23% w/w, 
83.82 ± 0.57% w/w, 88.52 ± 0.53% w/w, 93.87 ± 0.36% 
w/w and 93.34 ± 0.19% w/w, respectively. These figures 
reveal that as temperature increases, the percentage of 
drug loading also increases rapidly up to 50°C.Increase 
in temperature above 50°C did not further increase the 
percentage drug loading. Increased temperature during 
complexation increases ionization of the drug and resin. 
Higher temperatures tend to increase the diffusion rate of 
ions by decreasing the thickness of the exhaustive exchange 
zone. Also, at increased temperatures, swelling of the resin 
takes place. Due to swelling, the ionic sites are open for 
exchange of counter ions.
The drug content in the resinate was found to be 98.55%. 
The dissolution profile of the drug showed complete drug 
release within 90 s. Results of evaluation of taste indicated 
complete masking of the bitter taste as no bitterness was 
felt in the drug–resin complex [Table 2].
Characterization of  resinate
The infrared spectra of drug, indion 234 resin and resinate 
are depicted in Figure 1. A broad band of bonded -OH 
of Ondansetron HCl was observed from 3481 to 3245.97 
cm-1. Indion 234 shows characteristic peaks at 1674 cm-1, 
corresponding to –C=O stretching of aryl acids and due 
to aromatic C=C stretching. The absence of a peak at 
3,481–3,245.97 cm-1 in DRC  confirms the complexation 
of the secondary amine group in the drug with resin.
The X-ray diffraction study of drug shows the highly 
crystalline nature. Resin indion 234 showed an amorphous 
nature and the resinate showed noncrystalline characteristics. 
This might be because of entrapment of the drug molecule 
in the polymer matrix of the resins. From all the evidences, 
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it can be concluded that the drug resinate was a chemical 
complex [Figure 2]. Studies have shown that the molecules 
of the entrapped drug change from a crystalline to an 
amorphous state.[17]
The batches of controlled formulations and formulations 
containing superdisintegrant were designed using higher 
and lower concentrations of sodium starch glycolate and 
employing different filler binders and compressed on a 
tableting machine. For each designed formulation, the 
blend of drug and excipients was prepared and evaluated 
for micromeritic properties [Table 3]. The powder was 
found to be irregular in shape, as shown in Figure 3. Bulk 
density was found to be between 0.71 and 0.83 g/cm3 
and the tapped density was found to be between 0.73 and 
0.89 g/cm3 for all formulations. From density data, % 
compressibility was calculated and was found to be between 
5.55 and 6.66%. Angle of repose was found to be in the 
range of 30–33. The results showed that the resinates have 
good flow properties and packing abilities.
Evaluation of  tablets
The prepared batches (B1–B8) of tablets were evaluated 
for various official and unofficial parameters. Tablets 
obtained were of uniform weight due to uniform die fill, 
with acceptable variations as per IP specifications. The 
hardness, friability and uniformity of content are given in 
Table 4. Hardness of the tablets for each formulation was 
Table 2: Volunteers’ opinion test for Ondansetron HCl before and after taste masking by a panel of nine members 
using the time intensity method (n = 9)
Ingredients Formulations
B1 B2 B3 B4 B5 B6 B7 B8
Indion 234 resinate (mg) 9* 9 9 9 9 9 9 9
Sodium starch glycolate (mg) ---- ---- 4.5 6 7.5 4.5 6 7.5
Starlac (mg) 111 ---- 106.5 105 103.5 ---- ---- ----
Avicel (PH 101) ---- 111 ---- ---- ---- 106.5 105 103.5
Fructose 25 25 25 25 25 25 25 25
Aspartame 1 1 1 1 1 1 1 1
Magnesium stearate 2 2 2 2 2 2 2 2
Aerosil 2 2 2 2 2 2 2 2
Orange flavor QS QS QS QS QS QS QS QS
Total (mg) 150 150 150 150 150 150 150 150
P<0.001**
Table 3: Micromeritic properties of the powder blend*
Formulation Evaluation parameters
Shape Angle of repose Bulk density 
(g/cm3)





B1 Irregular 32.53 ± 0.38 0.806 ± 0.38 0.862 ± 0.76 6.4 ± 0.52 1.0695 Excellent
B2 Irregular 31.65 ± 0.18 0.7142 ± 0.38 0.7575 ± 0.19 5.716 ± 0.24 1.06 Excellent
B3 Irregular 32.82 ± 0.57 0.8333 ± 0.38 0.8928 ± 0.09 6.6644 ± 0.38 1.0714 Excellent
B4 Irregular 33.00 ± 0.43 0.7552 ± 0.38 0.7812 ± 0.87 5.888 ± 0.35 1.0625 Excellent
B5 Irregular 31.75 ± 0.21 0.7142 ± 0.38 0.7575 ± 0.25 5.7161 ± 0.96 1.060 Excellent
B6 Irregular 30.45 ± 0.87 0.6944 ± 0.38 0.7352 ± 0.31 5.549 ± 0.82 1.058 Excellent
B7 Irregular 32.39 ± 0.64 0.7245 ± 0.38 0.7744 ± 0.54 6.443 ± 0.49 1.0688 Excellent
B8 Irregular 31.72 ± 0.31 0.7178 ± 0.38 0.7674 ± 0.61 6.463 ± 0.73 1.069 Excellent
*Average of three determinations
Table  4: Evaluation of tablets* (batch B1–B8)
Evaluation parameters Formulations
B-1 B-2 B-3 B-4 B-5 B-6 B-7 B-8
Hardness (kg/cm2) 2.8±0.6 2.9±0.6 2.9±0.3 3.1±0.6 3.3±0.3 2.8±0.4 2.7±0.8 2.8±0.3
Friability (%w/w) 0.63±0.3 0.75±0.3 0.81±0.8 0.65±0.38 0.67±0.2 0.53±0.3 0.79±0.7 0.44±0.3
Drug content (%w/w) 98.16±0.8 97.05± 0.4 98.37±0.2 99.16±0.9 98.15±0.8 100.16±0.2 102.11±0.3 99.81±0.3
% Weight variation 3.45 ±0.7 4.04 ±0.6 1.43 ±0.4 2.08±1.6 2.78±0.5 2.24 ±0.8 3.87±3.9 3.18±0.6
Water absorption ratio 76.25±0.4 66.36 ±0.7 88.17±0.3 99.36±1.4 113.48±0.5 92.42±0.8 99.14±3.9 106.44±0.
Disintegration time (sec)  In vitro 60±1.0  51±0.6 30 ±0.6 28± 0.8 24 ±0.4 35 ±0.6  29±1.2 27± 0.9
In vivo 76±0.4 63±0.4 40±0.2 35±0.6 27±0.6 45±0.8 36±0.5 31±1.1
*Results are the mean of 3 observations ± SD.
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between 2.8 and 3.3 kg/cm2. Friability below 1.0% was an 
indication of good mechanical resistance of the tablets. The 
uniformity of content was found to be 97–102%, which 
was within the acceptable limits.
Sodium starch glycolate is widely used in oral pharmaceuticals 
as a disintegrant in tablet formulations. Sodium starch 
glycolate is the sodium salt of a carboxymethyl ether 
of starch. The water absorption ratio, in vivo and in vitro 
dispersion time are given in Table 4. It was revealed that 
as the concentration of sodium starch glycolate increases, 
the water absorption ratio increases and the in vivo and in 
vitro dispersion time decreases. But, in the formulations 
containing starlac as filler and binder, it was observed 
that sodium starch glycolate does not seem to have 
much significant effect on the water absorption ratio and 
dispersion time of the tablets. This may be due to the 
fact that starlac consists of 15% starch and 85% lactose. 
Starch has a good disintegrating ability and thus enhances 
water uptake and dispersion ability. In tablets containing 
microcrystalline cellulose as filler binder, sodium starch 
glycolate shows a significant effect on water absorption 
and dispersion time. This may be attributed to the fact 
that microcrystalline cellulose is a swellable material and its 
disintegration characteristics in water have been attributed 
to the capillary action or swelling.[18]
Dissolution rate was studied for all the tablet formulations 
and the conventional marketed tablet. For all designed 
formulations, the tablets show about 98% drug release within 
5 min, while the conventional marketed tablet required 9 
min for complete release of the drug [Figures 4 and 5]. The 
formulation B5 containing starlac as filler binder and sodium 
starch glycolate, showed complete drug release within 2 min 
[Figure 4] and formulation B8, containing microcrystalline 
cellulose as filler binder and sodium starch glycolate, showed 
complete drug release within 3 min [Figure 5]. The drug 
release from all formulations was too fast as compared to 
the conventional marketed tablet (B9).
CONCLUSION
Use of cation exchange resin offers a  good method 
for preparing taste-masked substrates of Ondansetron 
HCl. Results obtained in this work show that drug–
Figure 3: Particle shape of (A) indion 234 resins, (B) indion-234 resinate
(A) (B)
Figure 2: X-ray diffraction pattern of (A) Ondansetron HCl, (B) indion 




Figure 1: FT-IR spectra of (A) Ondansetron HCl (3,481–3,245.97 cm-
1), (B) indion 234 resin (1,674 cm-1), (C) indion-234 resinate
(A)
(B) (C)
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Figure 5: Dissolution profile of control tablet, tablets containing sodium 
starch glycolate containing MCC as filler binder and the marketed 
formulation
Figure 4: Dissolution profile of control tablet, tablets containing sodium 
starch glycolate containing starlac as filler binder and the marketed 
formulation
resin complexes effectively masked the bitter taste of 
Ondansetron HCl. Formulated ODTs showed good release 
profile, having an additional advantage of complete taste 
masking. Thus, complexation of Ondansetron HCl with 
indion 234 increases the acceptability and palatability of 
the formulated ODTs.
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